四海國際(00120.HK)擬進行股份互換兼10合1 世城系復牌
世城系公布,建議進行股份互換,以精簡資本結構,涉及百利保(00617.HK)與富豪(00078.HK)各持股50%百富控股所持AMTD 950萬股,每股價格8.45元;及四海國際(00120.HK)3.68億股,每股作價1.7元。完成後,四海公眾持股將減至低於25%,建議事項將無法進行。為此,公司建議進行股份10合1以及發行紅利股份,基準每持有1股合併股份獲2股紅股。
股份互換及發行紅股後,百富控股於AMTD持股將由1,517.4萬股減至567.4萬股,佔其總股本1.21%;於四海持股則由目前49.34%增至69.59%。
世紀城市(00355.HK)、百利保及四海股份申請周三(12日)起恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.